BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Decreased by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 34.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,671 shares of the biotechnology company’s stock after selling 4,029 shares during the quarter. Janney Montgomery Scott LLC’s holdings in BioMarin Pharmaceutical were worth $504,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC grew its stake in BioMarin Pharmaceutical by 56.1% during the 3rd quarter. GAMMA Investing LLC now owns 782 shares of the biotechnology company’s stock worth $55,000 after buying an additional 281 shares during the last quarter. CWM LLC lifted its holdings in shares of BioMarin Pharmaceutical by 363.1% in the third quarter. CWM LLC now owns 11,106 shares of the biotechnology company’s stock valued at $781,000 after buying an additional 8,708 shares during the period. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in shares of BioMarin Pharmaceutical by 437.5% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,720 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 1,400 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of BioMarin Pharmaceutical by 87.2% in the third quarter. Exchange Traded Concepts LLC now owns 16,663 shares of the biotechnology company’s stock valued at $1,171,000 after buying an additional 7,760 shares during the period. Finally, Creative Planning lifted its holdings in shares of BioMarin Pharmaceutical by 20.9% in the third quarter. Creative Planning now owns 14,300 shares of the biotechnology company’s stock valued at $1,005,000 after buying an additional 2,475 shares during the period. 98.71% of the stock is currently owned by institutional investors.

Insider Transactions at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total transaction of $350,300.86. Following the sale, the executive vice president now owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.85% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on BMRN shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $90.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, December 12th. Evercore ISI cut their target price on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. UBS Group upped their price target on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wolfe Research started coverage on BioMarin Pharmaceutical in a research report on Friday, November 15th. They set an “outperform” rating and a $95.00 price target on the stock. Finally, Canaccord Genuity Group dropped their price target on BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a research report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $94.20.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $63.93 on Monday. BioMarin Pharmaceutical Inc. has a 1-year low of $60.63 and a 1-year high of $94.85. The firm has a market capitalization of $12.18 billion, a PE ratio of 38.28, a PEG ratio of 0.57 and a beta of 0.28. The business’s 50 day moving average is $64.97 and its 200-day moving average is $72.17. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.